

European Heart Journal

Volume 46 No. 19 May 2025

ISSUE @ A GLANCE



New treatments and biomarkers in heart failure, hypertrophic cardiomyopathy, and familial hypercholesterolaemia

F. Crea

1777

CardioPulse

From data to perception: visualizing bias in artificial intelligence-generated images

P. Szymański, M. Lipczyńska, and A.M. Górska

1781

TAVI or TAVR: it is time to use a single standardized acronym for percutaneous aortic valve implantation

C. Indolfi, G. Esposito, and T.F. Lüscher

1783

An update on the ESC Council on Cardiovascular Genomics: out from the niche into the open

S. Kääh and A. Bondue

1784

FOCUS ISSUE ON HEART FAILURE AND CARDIOMYOPATHIES, EPIDEMIOLOGY, PREVENTION AND HEALTH CARE POLICIES

STATE OF THE ART REVIEW



Therapeutic left-to-right shunting in heart failure

F. Fioretti, A.P. Nair, S.D. Anker, B.A. Borlaug, D.J. Kereiakes, J. Lindenfeld, G.W. Stone, and J. Butler

1787

CLINICAL RESEARCH



High intensity exercise programme in patients with hypertrophic cardiomyopathy: a randomized trial

J. Basu, D. Nikolettou, C. Miles, H. MacLachlan, G. Parry-Williams, F. Tilby-Jones, P. Bulleros, Z. Fanton, C. Baker, S. Purcell, C. Lech, T. Chapman, P. Sage, S. Wahid, N. Sheikh, S. Jayakumar, A. Malhotra, T. Keteepe-Arachi, B. Gray, G. Finocchiaro, G. Carr-White, E. Behr, M. Tome, J. O'Driscoll, I. Chis Ster, S. Sharma, and M. Papadakis

1803

Editorial

Exercise prescription in hypertrophic cardiomyopathy: Dr Lown's lesson to break taboos

I. Olivotto and F. D'Ascenzi

1816

Fibroblast growth factor 5: a novel biomarker for familial hypercholesterolaemia

A. Baragetti, A.S. Alieva, L. Grigore, F. Pellegatta, A. Lupi, C. Scrimali, A.B. Cefalù, B.A. Hutten, A. Wiegman, P. Knaapen, M.J. Bom, N.S. Nurmohamed, O. Reutova, A. Konradi, E. Shlyakhto, E.S.G. Stroes, M. Averna, and A.L. Catapano

1819

Expanding the triglyceride range in clinical trials: therapeutic opportunities

A.T. Nordestgaard, A.D. Pradhan, B.M. Everett, J.G. MacFadyen, D.L. Bhatt, F.L.J. Visseren, P. Libby, R.D. Santos, S.E. Nissen, B.G. Nordestgaard, and P.M. Ridker

1835

Editorial

Reaching for the stars: a wider perspective for designing future cardiovascular outcome trials of triglyceride-lowering therapies

G.F. Watts and D.C. Chan

1849



High temperature and cardiovascular disease in Australia under different climatic, demographic, and adaptive scenarios

J. Liu, B.M. Varghese, A. Hansen, K. Dear, T. Driscoll, Y. Zhang, G. Morgan, V. Prescott, V. Dolar, M. Gourley, A. Capon, and P. Bi

1852

RAPID COMMUNICATIONS



Autophagy is required for the therapeutic effects of the NAD⁺ precursor nicotinamide in obesity-related heart failure with preserved ejection fraction

M. Abdellatif, F. Vasques-Nóvoa, V. Trummer-Herbst, S. Durand, F. Koser, M. Islam, J. Nah, E.-A. Sung, R. Feng, F. Aprahamian, A. Prokesch, P. Zardoya-LaGuardia, J. Sadoshima, A. Diwan, W.A. Linke, J.P. Ferreira, G. Kroemer, and S. Sedej

1863

DISCUSSION FORUM

Cardiovascular safety of assisted reproductive technologies: what have we learned and what remains unknown?

Z. Liang, D. Wang, and X. Wang

1867

Cardiovascular safety of assisted reproductive technologies: what is next?

C.A. Pivato and G. Stefanini

1869

CARDIOVASCULAR FLASHLIGHTS

Renal artery stenosis from dislodged occluder

Q. Yang, R. Wang, and M. Liu

1871

WEEKLY JOURNAL SCAN

Weekly Journal Scan: Myocarditis related to COVID-19 mRNA vaccination has less severe course than those associated to SARS-Cov-2 infection or conventional aetiology

L. Galiuto and M. Volpe

1872



This paper is Editor's Choice and is available free online at <https://academic.oup.com/eurheartj>



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>

previous

article

failure

Univ

duce

rial p

pulm

pitaliz

functi

non-p

prove

as a p

prove

carries

tions. R

vary b

resista

discuss

ongoing

The fo

patients

a Clinic

program

a rand

London

ility of a

licy out

for a 12

usual care

ment



www.eurheartj.org